Table 2.
Lipid and other biomarkers at baseline and after the ezetimibe add-on therapy
| Biomarkers | Baseline | At 22 weeks of Ezetimibe add-on therapy | p-value |
| Triglyceride (mg/dL) | 187 ± 109 | 134 ± 66 (-28%) | 0.010 |
| LDL-cholesterol (mg/dL) | 134 ± 20 | 102 ± 13 (-24%) | 0.020 |
| HDL-cholesterol (mg/dL) | 52 ± 11 | 56 ± 10 | 0.612 |
| Free fatty acid (μEq/L) | 377 ± 232 | 379 ± 204 | 0.726 |
| RLP-cholesterol (mg/dL) | 9.9 ± 7.0 | 8.8 ± 5.3 | 0.188 |
| Apolipoprotein B (mg/dL) | 107 ± 17 | 87 ± 12 (-18%) | 0.004 |
| Apolipoprotein A-I (mg/dL) | 134 ± 22 | 141 ± 23 | 0.121 |
| MDA-LDL (mg/dL) | 113 ± 28 | 100 ± 28 (-12%) | 0.039 |
| Glucose (mg/dL) | 118 ± 24 | 110 ± 16 | 0.152 |
| HbA1c (%) | 5.9 ± 0.7 | 6.0 ± 0.8 | 0.531 |
| hs-CRP (mg/dL) | 0.11 ± 0.09 | 0.13 ± 0.18 | 0.872 |
| dROMs (U Carr) | 368 ± 47 | 329 ± 45 (-11%) | 0.014 |
Data are expressed as mean ± SD or as number (%). The Student's paired t-test was used for pairwise comparisons between values before and after administration of ezetimibe for 22 weeeks (n = 14). RLP, remnant lipoprotein; MDA, malondialdehyde-modified; hs-CRP, high-sensitivity C reactive protein; dROMs, derivatives of the reactive oxidative metabolites.